• CF PharmTech’s marketing authorization application for tiotropium bromide inhalation powder was accepted for review by China’s NMPA.
• The product targets COPD bronchospasm treatment, including reducing exacerbations.
• The filing acceptance does not grant marketing approval; the application remains subject to further regulatory review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260526-12170036), on May 26, 2026, and is solely responsible for the information contained therein.